糖尿病性胃不全麻痺:パイプラインレビュー2019下半期

【英語タイトル】Diabetic Gastroparesis - Pipeline Review, H2 2019

Global Markets Directが出版した調査資料(GDATA9120314)・商品コード:GDATA9120314
・発行会社(調査会社):Global Markets Direct
・発行日:2019年11月
・ページ数:73
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後24時間以内)
・調査対象地域:グローバル
・産業分野:製薬及び医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,000 ⇒換算¥216,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥432,000見積依頼/購入/質問フォーム
Enterprisewide Price(複数事業所内共有可)USD6,000 ⇒換算¥648,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Diabetic Gastroparesis – Pipeline Review, H2 2019
Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Gastroparesis – Pipeline Review, H2 2019, provides an overview of the Diabetic Gastroparesis (Gastrointestinal) pipeline landscape.

Gastroparesis is a long-term complication of diabetes that involves the stomach and affects digestion. Prolonged high blood sugar levels can damage nerves in many parts of the body, including the vagus nerve, which controls contractions of the stomach during digestion. Spasms, abdominal pain, feelings of fullness after a small amount of food, and other symptoms such as nausea and vomiting, reflux, heartburn, and bloating are often experienced with gastroparesis. Loss of appetite and reduced absorption of nutrients may also be experienced. Gastroparesis can lead to weight loss and malnutrition.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Diabetic Gastroparesis – Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Diabetic Gastroparesis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diabetic Gastroparesis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Gastroparesis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II and Phase I stages are 1, 3, 6 and 1 respectively.

Diabetic Gastroparesis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Gastroparesis (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Diabetic Gastroparesis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Diabetic Gastroparesis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Diabetic Gastroparesis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Gastroparesis (Gastrointestinal)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Diabetic Gastroparesis (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Diabetic Gastroparesis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Diabetic Gastroparesis – Overview
Diabetic Gastroparesis – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Diabetic Gastroparesis – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Diabetic Gastroparesis – Companies Involved in Therapeutics Development
AlfaSigma SpA
Allergan Plc
Bird Rock Bio Inc
Censa Pharmaceuticals Inc
CinRx Pharma LLC
ETX Pharma Inc
Evoke Pharma Inc
Johnson & Johnson
Takeda Pharmaceutical Co Ltd
Vanda Pharmaceuticals Inc
Diabetic Gastroparesis – Drug Profiles
CIN-102 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CNSA-001 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ETX-101 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
metoclopramide – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nimacimab – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
prucalopride succinate – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
relamorelin – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
renzapride – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAK-906 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tradipitant – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
velusetrag – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Diabetic Gastroparesis – Dormant Projects
Diabetic Gastroparesis – Discontinued Products
Diabetic Gastroparesis – Product Development Milestones
Featured News & Press Releases
May 17, 2019: Allergan expands PLEDGE Clinical Research Program in Diabetic Gastroparesis
Dec 03, 2018: Vanda announces positive phase II study results for Tradipitant in patients with gastroparesis
Oct 08, 2018: Allergan to present data on Relamorelin at ACG 2018
May 15, 2018: EndoLogic Announces FDA Accepts Cardiac Safety Trial for Renzapride in Patients with Gastroparesis
Aug 09, 2017: EndoLogic Announces Feedback from Positive FDA Meeting for Renzapride in Diabetic Gastroparesis
May 03, 2017: EndoLogic Announces Scheduling of pre-IND Meeting with FDA to Discuss Renzapride in Diabetic Gastroparesis
May 01, 2017: Allergan to Present Data on Relamorelin at Digestive Disease Week 2017
Dec 06, 2016: Theravance Biopharma Receives FDA Fast Track Designation for Velusetrag (TD-5108) for Idiopathic and Diabetic Gastroparesis
Apr 04, 2016: Motus Completes Enrollment of Phase 2b Clinical Trial of Relamorelin for Diabetic Gastroparesis
Apr 08, 2015: Rhythm Initiates Phase 2b Clinical Trial of Relamorelin for Diabetic Gastroparesis
May 06, 2014: Rhythm Presents Positive Phase 2 Study Results for Ghrelin Prokinetic Relamorelin (RM-131) in Diabetic Gastroparesis
May 20, 2013: Rhythm Announces Phase Ib Results For Ghrelin Prokinetic RM-131 For Gastroparesis In Patients With Type 1 Diabetes
Oct 22, 2012: Rhythm Announces Positive Phase I Results For Ghrelin Prokinetic RM-131 For Treatment Of Diabetic Gastroparesis
Jun 06, 2012: Rhythm Initiates Phase II Clinical Trial Of Ghrelin Prokinetic RM-131 For Diabetic Gastroparesis
May 22, 2012: Rhythm Announces Phase Ib Results Of RM-131 For Diabetic Gastroparesis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Diabetic Gastroparesis, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Diabetic Gastroparesis - Pipeline by AlfaSigma SpA, H2 2019
Diabetic Gastroparesis - Pipeline by Allergan Plc, H2 2019
Diabetic Gastroparesis - Pipeline by Bird Rock Bio Inc, H2 2019
Diabetic Gastroparesis - Pipeline by Censa Pharmaceuticals Inc, H2 2019
Diabetic Gastroparesis - Pipeline by CinRx Pharma LLC, H2 2019
Diabetic Gastroparesis - Pipeline by ETX Pharma Inc, H2 2019
Diabetic Gastroparesis - Pipeline by Evoke Pharma Inc, H2 2019
Diabetic Gastroparesis - Pipeline by Johnson & Johnson, H2 2019
Diabetic Gastroparesis - Pipeline by Takeda Pharmaceutical Co Ltd, H2 2019
Diabetic Gastroparesis - Pipeline by Vanda Pharmaceuticals Inc, H2 2019
Diabetic Gastroparesis - Dormant Projects, H2 2019
Diabetic Gastroparesis - Discontinued Products, H2 2019

List of Figures
Number of Products under Development for Diabetic Gastroparesis, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products by Targets, H2 2019
Number of Products by Stage and Targets, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019

【掲載企業】

AlfaSigma SpA
Allergan Plc
Bird Rock Bio Inc
Censa Pharmaceuticals Inc
CinRx Pharma LLC
ETX Pharma Inc
Evoke Pharma Inc
Johnson & Johnson
Takeda Pharmaceutical Co Ltd
Vanda Pharmaceuticals Inc

★調査レポート[糖尿病性胃不全麻痺:パイプラインレビュー2019下半期] (コード:GDATA9120314)販売に関する免責事項を必ずご確認ください。
★調査レポート[糖尿病性胃不全麻痺:パイプラインレビュー2019下半期]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆